ARWR - Total Utang marang Modal Arrowhead Corp

Logo perusahaan publik Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals (ARWR) is automating the search for liver therapy formulas by integrating AI and robotics into laboratory processes. The price action for the separate_debt_total_eq metric is 2.87. The business relies on RNA interference to create an extensive pipeline of drugs for the heart, lungs, and hepatology, which effectively diversifies investment risks and minimizes potential losses from failures in individual clinical trials.

ARWR: Total Utang marang Modal Arrowhead Pharmaceuticals, Inc. 04.07.2022 - 30.10.2026

Rincian analitis perusahaan Arrowhead Pharmaceuticals

- rega lan prakiraan konsensus rega:
Bagan rega Arrowhead Pharmaceuticals, Inc.|ARWR - Bagan tingkat prakiraan
- statistik kapitalisasi pasar:
Kapitalisasi pasar Arrowhead Pharmaceuticals|ARWR - Nilai Dipunlarasaken Utang lan Kas
- indikator kapitalisasi buku:
Nilai Buku saben Saham Arrowhead Pharmaceuticals|ARWR - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku arrowheadpharma.com|ARWR - Nilai Agregat Aset
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Arrowhead Pharmaceuticals|ARWR - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Arrowhead Pharmaceuticals|ARWR - Gunggung utang perusahaan|Utang marang nilai buku Arrowhead Pharmaceuticals|ARWR - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Arrowhead Pharmaceuticals|Rasio cepet arrowheadpharma.com
- informasi bathi lan kelipatan valuasi:
ARWR - Asil keuangan resik
Analisis dhasar perusahaan:Arrowhead Pharmaceuticals, Inc.
Barang utama Arrowhead Corp

The total debt-to-equity ratio measures the degree of financial leverage by comparing total liabilities to equity to assess the stability of the financing structure. By analyzing changes in the total debt-to-equity ratio, an investor can determine whether Arrowhead Pharmaceuticals (ARWR) possesses sufficient resources to commercialize RNAi therapy without imposing a critical debt burden on its capital.

Analisis pesaing Arrowhead Pharmaceuticals

Utang marang Ekuitas Mirum|Dynavax - Utang Agregat marang Ekuitas|Total Utang marang Modal ABUS|IVA (Inventiva Corp) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal GYRE (Gyre Therapeutics, Inc.)|Total Utang marang Modal assemblybio.com ASMB|GALT - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi GNFT (Genfit S.A.)|durect.com (DRRX) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Aligos Therapeutics, Inc.|BIVI (BioVie Inc) - Total Utang marang Modal|Total Utang marang Modal Galmed Pharma|Rasio Total Utang marang Ekuitas NDRA (ENDRA Life Sciences Inc.)|HEPA (hepionpharma.com) - Rasio Kabeh Utang marang Dana Pribadi